At a glance
- Originator GlaxoSmithKline
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 19 Nov 1997 Preclinical development for Hypercholesterolaemia in USA (Unknown route)